NKTR
Nektar Therapeutics Health Care Pharmaceutical Preparations Russell 3000
$38.87Close
$792.1MMarket cap
$35.12 – $100.3552-week range
Nov 5, 2026Next report
Highlights
Cautions
- Not in an uptrend 1 of 8 trend conditions
- Lagging the market RS 6 · weaker than 94% of stocks over 12 months
- Far from its high 61% below its 52-week high
- Distribution down-day volume 2.0× up-day volume over 50 sessions
- Results soon Nov 5, 2026, in 4 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
61%
1wk
up 4.4%
price change
1mo
down 35.8%
price change
12-month return
down 38%
market up 11% ·
its own down 46%
F-score
3 / 9
Weak
Altman Z
-16.82
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
8.8×
price / book
Earnings yield
down 18.0%
EBIT / enterprise value
Cheaper than
8%
of the market · expensive
Revenue growth
down 44%
year on year
EPS growth
—
latest quarter
Sales growth
down 9%
latest quarter · -13 pts
ROE
down 218%
return on equity
Free cash margin
down 378%
-$208.7M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- profitability slipped from last year
- profits not fully backed by cash
- issued more shares
- assets working less efficiently
- reduced long-term debt
- short-term liquidity improved
- gross margin widened
Repair signals
- Gross margin 68.8% → 100.0%
Trade setup
ATR%
5.9%
$2.31 a day · 2×ATR $34.26
RS
6 / 99
vs the universe
Trend
1 / 8
trend template
Relative volume
0.5×
vs 50-day average
Up/down volume
0.50
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 1 of 8
- 150-day average above the 200-day: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 64.5% over the year, from 12m to 20m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Revenue shrinking Revenue fell 43.9% over the year, from $98.4M to $55.2M.
Last reported
Aug 13, 2026
Last shock
Oct 1, 2026-22% in one session6.0× volumeon an SEC filing-17% since
Financials
- Gross 100%
- Net -297%
- Free cash -378%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $152.9M | $101.9M | $92.1M | $90.1M | $98.4M | $55.2M |
| Gross margin | 87% | 76% | 76% | 63% | 69% | 100% |
| Operating income | -$425.1M | -$446.1M | -$376.2M | -$263.7M | -$105.2M | -$140.1M |
| Net income | -$444.4M | -$524.0M | -$368.0M | -$276.0M | -$119.0M | -$164.0M |
| Net margin | -291% | -514% | -400% | -306% | -121% | -297% |
| Earnings per share | -$35.55 | -$40.84 | -$28.09 | -$20.75 | -$8.68 | -$9.72 |
| Free cash flow | -$320.5M | -$427.6M | -$309.7M | -$193.5M | -$177.2M | -$208.7M |
| Free cash margin | -210% | -420% | -336% | -215% | -180% | -378% |
| Cash | $199.0M | $25.2M | $88.2M | $35.3M | $44.3M | $15.1M |
| Shareholders' equity | $1.1B | $679.5M | $366.6M | $131.0M | $60.7M | $89.8M |
| Shares outstanding | 12.61m | 12.98m | 13.20m | 13.40m | 12.39m | 20.38m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 14, 2026 | Quarterly ↗ | Jun 30, 2026 | 45d |
| May 8, 2026 | Quarterly ↗ | Mar 31, 2026 | 38d |
| Mar 13, 2026 | Annual ↗ | Dec 31, 2025 | 72d |
| Nov 7, 2025 | Quarterly ↗ | Sep 30, 2025 | 38d |
| Aug 8, 2025 | Quarterly ↗ | Jun 30, 2025 | 39d |
| May 9, 2025 | Quarterly ↗ | Mar 31, 2025 | 39d |
| Mar 14, 2025 | Annual ↗ | Dec 31, 2024 | 73d |
| Nov 8, 2024 | Quarterly ↗ | Sep 30, 2024 | 39d |
| Aug 9, 2024 | Quarterly ↗ | Jun 30, 2024 | 40d |
| May 10, 2024 | Quarterly ↗ | Mar 31, 2024 | 40d |
| Mar 5, 2024 | Annual ↗ | Dec 31, 2023 | 65d |
| Nov 8, 2023 | Quarterly ↗ | Sep 30, 2023 | 39d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 1, 2026 | Regulation FD ↗ |
| Sep 25, 2026 | Other events ↗ |
| Sep 8, 2026 | Regulation FD ↗ |
| Aug 13, 2026 | Results ↗ |
| Jun 5, 2026 | Shareholder vote ↗ |
| May 8, 2026 | Material agreement · Director or officer change ↗ |
| May 7, 2026 | Results ↗ |
| Apr 23, 2026 | Material agreement · Other events ↗ |
| Apr 20, 2026 | Regulation FD ↗ |
| Apr 20, 2026 | Regulation FD · Other events ↗ |
| Mar 12, 2026 | Results ↗ |
| Feb 13, 2026 | Material agreement · Other events ↗ |